Lion Point Capital, LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001643354

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltBuy & Hold how tags are computed

Q2 2024 · 27 positions · Total reported value $54.85M · Top-10 concentration 82.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 2.9% · 0 new · 1 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +28.8% · vs SPY +14.0% · Prev Value $16.73M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2024 13F filing, Lion Point Capital, LP disclosed 27 equity positions with a combined reported value of $54.85M. The filing implies a focused portfolio: its ten largest positions account for 82.9% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / Buy & Hold.

The largest disclosed positions as of Q2 2024 were IWM ($16.74M), ARDX ($6.35M), INSM ($4.71M). By sector, the heaviest allocations are Health Care 50.0%, Technology 0.1%. Versus the prior quarter, allocation shifted toward Health Care (+24.3pp) and away from Other (-24.3pp).

Versus the prior quarter, Lion Point Capital, LP opened 0 new positions, trimmed 1 and fully exited 0, a turnover rate of 2.9% of positions. The portfolio's overlap with the prior quarter was 84% of names.

The largest new positions opened in Q2 2024 were BBIO ($1.24M).

Of the 4 positions fully exited versus the prior quarter, the largest were HUMA ($730.85K), TVTX ($601.38K), REPL ($347.23K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

  • BBIO BRIDGEBIO PHARMA INC · $1.24M

Fully Exited (vs previous quarter)

  • HUMA HUMACYTE INC · prev qtr: $730.85K · history
  • TVTX TRAVERE THERAPEUTICS INC · prev qtr: $601.38K
  • REPL REPLIMUNE GROUP INC · prev qtr: $347.23K
  • SMTC SEMTECH CORP · prev qtr: $385

Insider Transactions (Form 4)

Latest Lion Point Capital, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Lion Point Capital, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 35 US equity positions with a combined value of $20.91M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-81004 (status: Approved), registered 2015-02-25
  • Regulatory AUM (Form ADV): $480.60M as of 2026-04-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 5 private funds, of which 2 hedge funds
  • Website: lionpoint.com

Portfolio Structure

  • 35 positions · $20.91M reported value (Q2 2026)
  • Top 10 holdings = 55.0% of reported value
  • Largest position: CUE (Cue Biopharma Inc) at 8.0%
  • Average position size: $597.29K

Sector Tilt

  • Health Care 98.8%
  • Information Technology 1.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 reduced
  • 34 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 50.0%
Technology 0.1%
Energy 0.0%
Other 49.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 82.50K $16.74M 30.52%
30.52%
Reduce
2 856.67K $6.35M 11.57%
11.57%
Reduce
3 70.33K $4.71M 8.59%
8.59%
Hold
4 50.00K $4.64M 8.45%
8.45%
Hold
5 2.34M $3.09M 5.63%
5.63%
Add
6 630.00K $2.67M 4.87%
4.87%
Add
7 2.11M $2.47M 4.51%
4.51%
Hold
8 104.69K $1.95M 3.56%
3.56%
Reduce
9 45.00K $1.54M 2.81%
2.81%
Hold
10 65.00K $1.33M 2.43%
2.43%
Hold
11 49.00K $1.24M 2.26%
2.26%
New
12 82.50K $1.16M 2.12%
2.12%
Hold
13 8.35K $1.15M 2.10%
2.10%
Add
14 170.00K $1.04M 1.89%
1.89%
Hold
15 79.00K $924.30K 1.69%
1.69%
Add
16 78.12K $857.81K 1.56%
1.56%
Hold
17 32.00K $726.40K 1.32%
1.32%
Hold
18 678.26K $667.54K 1.22%
1.22%
Reduce
19 2.75M $557.42K 1.02%
1.02%
Hold
20 36.25K $424.12K 0.77%
0.77%
Add
21 340.76K $246.64K 0.45%
0.45%
Hold
22 90.79K $210.64K 0.38%
0.38%
Hold
23 100 $44.70K 0.08%
0.08%
Hold
24 75.00K $38.83K 0.07%
0.07%
Hold
25 2.08M $26.25K 0.05%
0.05%
Hold
26 7.42K $24.79K 0.04%
0.04%
Reduce
27 100 $18.34K 0.03%
0.03%
Hold

FAQ

What did Lion Point Capital, LP buy in 2024-Q2?

In its 2024-Q2 13F filing, Lion Point Capital, LP reported 27 equity positions worth $54.85M in aggregate; its largest disclosed positions were IWM ($16.74M), ARDX ($6.35M), INSM ($4.71M).

How large is Lion Point Capital, LP's portfolio?

Lion Point Capital, LP reported $54.85M of long equity holdings across 27 positions as of 2024-Q2. Top-10 holdings account for 82.9% of reported value.

What is Lion Point Capital, LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/lion-point-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →